|
1
|
Ferlay J, Shin H, Bray F, Forman D,
Mathers C and Parkin D: GLOBOCAN 2008 v2.0. Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 10. International Agency
for Research on Cancer; Lyon: 2010, Available from: http://globocan.iarc.fr.
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
3
|
Im SS and Monk BJ: New developments in the
treatment of invasive cervical cancer. Obstet Gynecol Clin North
Am. 29:659–672. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peters WA III, Liu P, Barrett RJ II, et
al: Concurrent chemotherapy and pelvic radiation therapy compared
with pelvic radiation therapy alone as adjuvant therapy after
radical surgery in high-risk early-stage cancer of the cervix. J
Clin Oncol. 18:1606–1613. 2000.
|
|
5
|
Morris M, Eifel PJ, Lu J, et al: Pelvic
radiation with concurrent chemotherapy compared with pelvic and
para-aortic radiation for high-risk cervical cancer. N Engl J Med.
340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rose PG, Bundy BN, Watkins EB, et al:
Concurrent cisplatin-based radiotherapy and chemotherapy for
locally advanced cervical cancer. N Engl J Med. 340:1144–1153.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whitney CW, Sause W, Bundy BN, et al:
Randomized comparison of fluorouracil plus cisplatin versus
hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA
carcinoma of the cervix with negative para-aortic lymph nodes: a
Gynecologic Oncology Group and Southwest Oncology Group study. J
Clin Oncol. 17:1339–1348. 1999.PubMed/NCBI
|
|
8
|
Keys HM, Bundy BN, Stehman FB, et al:
Cisplatin, radiation, and adjuvant hysterectomy compared with
radiation and adjuvant hysterectomy for bulky stage IB cervical
carcinoma. N Engl J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonomi P, Blessing JA, Stehman FB, DiSaia
PJ, Walton L and Major F: Randomized trial of three cisplatin dose
schedules in squamous-cell carcinoma of the cervix: a Gynecologic
Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
|
|
10
|
McGuire WP, Blessing JA, Moore D, Lentz SS
and Photopulos G: Paclitaxel has moderate activity in squamous
cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol.
14:792–795. 1996.PubMed/NCBI
|
|
11
|
Pectasides D, Kamposioras K, Papaxoinis G
and Pectasides E: Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore DH, Blessing JA, McQuellon RP, et
al: Phase III study of cisplatin with or without paclitaxel in
stage IVB, recurrent, or persistent squamous cell carcinoma of the
cervix: a Gynecologic Oncology Group Study. J Clin Oncol.
22:3113–3119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monk BJ, Sill MW, McMeekin DS, et al:
Phase III trial of four cisplatin-containing doublet combinations
in stage IVB, recurrent, or persistent cervical carcinoma: a
Gynecologic Oncology Group study. J Clin Oncol. 27:4649–4655. 2009.
View Article : Google Scholar
|
|
14
|
Wintrobe MM: Clinical Hematology. 3rd
edition. Henry Kimpton; London: 1951
|
|
15
|
Kim J, Bae SM, Lim DS, et al: Tetraarsenic
oxide-mediated apoptosis in a cervical cancer cell line, SiHa.
Cancer Res Treat. 37:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park SG, Jung JJ, Won HJ, et al:
Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of
solid tumors by anti-vascular effect. Cancer Lett. 277:212–217.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung WH, Sung BH, Kim SS, Rhim H and Kuh
HJ: Synergistic interaction between tetra-arsenic oxide and
paclitaxel in human cancer cells in vitro. Int J Oncol.
34:1669–1679. 2009.PubMed/NCBI
|
|
18
|
Benedet JL, Odicino F, Maisonneuve P, et
al: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 83(Suppl
1): 41–78. 2003. View Article : Google Scholar
|
|
19
|
Mandic A, Hansson J, Linder S and Shoshan
MC: Cisplatin induces endoplasmic reticulum stress and
nucleus-independent apoptotic signaling. J Biol Chem.
278:9100–9106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robati M, Holtz D and Dunton CJ: A review
of topotecan in combination chemotherapy for advanced cervical
cancer. Ther Clin Risk Manag. 4:213–218. 2008.PubMed/NCBI
|
|
21
|
Bonomi P, Blessing J, Ball H, Hanjani P
and DiSaia PJ: A phase II evaluation of cisplatin and
5-fluorouracil in patients with advanced squamous cell carcinoma of
the cervix: a Gynecologic Oncology Group study. Gynecol Oncol.
34:357–359. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Daghestani AN, Hakes TB, Lynch G and Lewis
JL: Cervix carcinoma: treatment with combination cisplatin and
bleomycin. Gynecol Oncol. 16:334–339. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cervellino JC, Araujo CE, Sánchez O, Miles
H and Nishihama A: Cisplatin and ifosfamide in patients with
advanced squamous cell carcinoma of the uterine cervix. A phase II
trial. Acta Oncol. 34:257–259. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duenas-Gonzalez A, Lopez-Graniel C,
Gonzalez A, et al: Phase II study of gemcitabine and cisplatin
combination as induction chemotherapy for untreated locally
advanced cervical carcinoma. Ann Oncol. 12:541–547. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pignata S, Silvestro G, Ferrari E, et al:
Phase II study of cisplatin and vinorelbine as first-line
chemotherapy in patients with carcinoma of the uterine cervix. J
Clin Oncol. 17:756–760. 1999.PubMed/NCBI
|
|
26
|
Rose PG, Blessing JA, Gershenson DM and
McGehee R: Paclitaxel and cisplatin as first-line therapy in
recurrent or advanced squamous cell carcinoma of the cervix: a
Gynecologic Oncology Group study. J Clin Oncol. 17:2676–2680.
1999.
|
|
27
|
Papadimitriou CA, Sarris K, Moulopoulos
LA, et al: Phase II trial of paclitaxel and cisplatin in metastatic
and recurrent carcinoma of the uterine cervix. J Clin Oncol.
17:761–766. 1999.PubMed/NCBI
|
|
28
|
Piver MS, Ghamande SA, Eltabbakh GH and
O’Neill-Coppola C: First-line chemotherapy with paclitaxel and
platinum for advanced and recurrent cancer of the cervix: a phase
II study. Gynecol Oncol. 75:334–337. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fiorica J, Holloway R, Ndubisi B, et al:
Phase II trial of topotecan and cisplatin in persistent or
recurrent squamous and non-squamous carcinomas of the cervix.
Gynecol Oncol. 85:89–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang N, Wu ZM, McGowan E, et al: Arsenic
trioxide and cisplatin synergism increase cytotoxicity in human
ovarian cancer cells: therapeutic potential for ovarian cancer.
Cancer Sci. 100:2459–2464. 2009. View Article : Google Scholar
|
|
31
|
Woo SH, Park MJ, An S, et al: Diarsenic
and tetraarsenic oxide inhibit cell cycle progression and bFGF-and
VEGF-induced proliferation of human endothelial cells. J Cell
Biochem. 95:120–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thigpen T, Vance R, Khansur T and Malamud
F: The role of paclitaxel in the management of patients with
carcinoma of the cervix. Semin Oncol. 24(1 Suppl 2): S2-41–S2-46.
1997.PubMed/NCBI
|
|
33
|
Rowinsky EK, Gilbert M, McGuire W, et al:
Sequences of taxol and cisplatin: a phase I and pharmacologic
study. J Clin Oncol. 9:1692–1703. 1991.PubMed/NCBI
|
|
34
|
Delaloge S, Laadem A, Taamma A, et al:
Pilot study of the paclitaxel, oxaliplatin, and cisplatin
combination in patients with advanced/recurrent ovarian cancer. Am
J Clin Oncol. 23:569–574. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gordinier M, Kudelka A, Kavanagh J,
Wharton J and Freedman R: Thiotepa in combination with cisplatin
for primary epithelial ovarian cancer: a phase II study. Int J
Gynecol Cancer. 12:710–714. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Serova M, Calvo F, Lokiec F, et al:
Characterizations of irofulven cytotoxicity in combination with
cisplatin and oxaliplatin in human colon, breast, and ovarian
cancer cells. Cancer Chemother Pharmacol. 57:491–499. 2006.
View Article : Google Scholar : PubMed/NCBI
|
